Theratechnologies Inc T.TH

AACR

[Biobob]

So we have AACR coming up on April 11 and Q2 around mid April and then AGM on April 10... now it's no news sub 3$ to celebrate the printing of March statements.. I guess they don't care because the Cancer data will solve everything soon I hope... with growing sales of 80M they can refinance the debenture without giving away shares, so selling here is plain stupidity even if you hate everything about the company.

[SPCEO1]

I have not seen any announcement on when the AGM is yet. Pre covid it was typcially in mid-May

[Bucknelly21]

It's nice to see thera is so proactive in supporting the stock if I was Soleus I would be looking at a loss right now thanks to the super incapable management 

[LouisW]

I think the meeting to report finacial result of Q1 will be at mid April. The feedback from FDA regarding the NASH trial oculd be received before the meeting and whether TH have DLT at 1.5x...We will hear the update soon. 

[Lee430]

Could it be the root problem is that PL is simply getting poor IR advice from whomever is advising him internally or externally? Could the solution simply be a candid conversation with PL from Wino that was kind enough to represent us last year, he could suggest to PL some IR solutions going forward, or the many seasoned investors here could put together a hit list of suggestions for him to

[Biobob]

Paul is NOT an entrepreneur, he's a big pharma big spending big budget guy he's not good at promoting his company. He his a rooky in finance and totally relies on his lame CFO for the financings and even worse IR now. I heard that that Gary Littlejohn is actually helping us in keeping the big spender in check. The science team is the best part of the company but is learning the ropes and

[SPCEO1]

Things may move faster than you think in phase 1b and phase 2. Eligble patients in the phase 1a will roll right into the phase 1b, giving that trial a head start with at least some patients. TH has also said as soon as they see signs of efficacy in phase 1b in one tumor type, they will take that to the FDA and get a phase 2 started in that ASAP. So, if things work out as we hope, we could have

[LouisW]

Are the patients in Phase 1b all SORT1+

[jfm1330]

The corporate presentation states that phase Ib will include SORT1+ patients with many types of cancers. The only way to be sure at this point that a patient is SORT1+, is by doing a biopsy and immunostaining of the cancer tissue. So my understanding is that inclusion criteria will require overexpressing sortilin confirmed by a biopsy, even though on Clinicaltrials.gov, they only mention "

[SPCEO1]

Yes, I believe you are correct. Paul is two years into the job now and there is no evidence I have seen that he understands all the aspects of IR that he needs to (he did come to the job without that experience) and the track record of TH on the IR front is undeniably at the lower end of the corproate spectrum. So it is not a great situation. They are all seemingly nice people and do a good job in

[Biobob]

Yes Wino.. It's time we actually do something about it because obviously Paul and the board are not.  Paul is fixating on operations and apart from the giving jobs to former collegues has done nothing for my investment.  I own this company and I will call the shot now.